The Science Journal of the American Association for Respiratory Care

2011 OPEN FORUM Abstracts

A NOVEL APPROACH TO SPIROMETRY SCREENING FOR COPD AND TOBACCO USE.

Scott Cerreta; American Lung Association in Arizona, Tucson, AZ

ABSTRACT: A total of 840 participants participated in ALAA Community Screening for COPD events from 2007 to May 2010. The ALAA protocol includes several documents and tools designed to maximize efficiency with minimal reliance on additional staff. The primary focus is to promote healthy lungs through tobacco prevention and cessation, raise awareness for COPD through lung health screens and spirometry testing, and connect participants with abnormal lung function to local physicians for further evaluation. The ALAA protocol includes several screening tools and steps to narrow spirometry testing to a small number of people with a valid indication to perform diagnostic spirometry. The results of this project are designed to evaluate the effectiveness of the ALAA COPD Community Screening model. Of the 840 participants that completed a COPD Population Screener, 684 (82%) had a screening score of less than 5 and 147 participants (21%) chose to have a COPD-6 test administered even though it was not indicated. And 21 of these 147 COPD-6 tests had a confirmed abnormal diagnostic spirometry test (14%). This confirms effectiveness of the COPD Population Screener as a suitable replacement for diagnostic spirometry as the screening tool. Results of 126 participants with a screener score of 5 or more, indicated that 59% had a normal COPD-6 test and 41% had an abnormal test. Of the 31 screeners who had an abnormal COPD-6 test and repeatable diagnostic spirometry, 25 screeners (81%) reported an abnormal repeatable diagnostic spirometry test. This data suggests the COPD-6 is a very effective tool at dwindling the participants down from 126 to 44 that needed to have a diagnostic spirometry test. Furthermore, a high percentage (88%) of the COPD-6 tests were confirmed by diagnostic spirometry to in fact reveal abnormal lung function. Sponsored Research - None